Etrasimod Results Justify Pfizer’s Leap Of Faith In Arena Buyout
Big Pharma Executed $6.7bn Deal Without Seeing Phase III Data
Executive Summary
Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: etrasimod comes through for Pfizer; PTC confident on gene therapy; could CAR-Ts roll into the community setting; the attractions of Boston for Korean bioventures; and Ukraine war may claim Sputnik casualties.
Pfizer Highlights Next I&I Star As Xeljanz Sales Fall
The company is looking to refuel its immunology & inflammation portfolio as Xeljanz safety takes a toll and the franchise approaches loss of exclusivity.
The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall
Blockbusters like Stelara, Eliquis, Prolia and Ibrance are poised to lose US exclusivity over the next five years; pressure is mounting for industry to replenish the portfolio with the next high-growth brands.